Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"zoledronic acid"”.
-
Effect of Zoledronic Acid on Maxillary Alveolar Bone Coverage in Rice Rats With and Without Dental Trauma
… of a potent intravenous nitrogen-containing BP, zoledronic acid (ZA), on maxillary alveolar bone loss in an established rat model of periodontal disease. The role of trauma was determined by comparing data from sites adjacent to and remote from dental extractions. A statistically significant …
-
The clinical characteristics, complications and treatment outcomes of patients with osteoporosis at Groote Schuur Hospital
… 80.8% (n=160) received intravenous zoledonic acid alone, 6.1% (n=12) received oral alendronate alone and 13.1% (n=26) initially received alendronate followed by intravenous zoledronic acid. Over 5.2 years there was an improvement in bone mineral density (BMD) of 4.4% at the lumbar spine, while …
-
Delineating the metastatic process in osteosarcoma; the role of bone cells, the cell environment and autophagy
… shows that targeting osteoclasts (OCs) with zoledronic acid (ZA) increases the number of metastatic lung lesions clinically, whereas treatment with Fulvestrant increases OC numbers and decreases metastatic lesions. This links OC function to OS metastasis. Through an in vitro model of OS …
-
Roles of γδ T Cells in Influenza Infections and Methods for TCR Expression and Characterization
… of a TRGV9/TRDV2 receptor that is activated by zoledronic acid. The functional activity of these α and γδ TCRs can be characterized in a novel reporter cell line (Nur77-GFP Jurkat 76 TCR-null) for screening of TCR specificity and avidity. In summary, we provide a rapid method for the cloning, …
-
An assessment of the oral health status and dental treatment needs of oncology patients receiving bone modifying agents
… 94% (n=142) were planned for intravenous (IV) zoledronic acid and 6% (n=8) were planned for subcutaneous (SC) denosumab. 37 patients were current smokers (24.7%), and 23 patients were ex-smokers (15.3%). 65 patients (43.3%) did not have a general dental practitioner (GDP) at the time of …